Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine ... The Herald | HeraldOnline.com The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... |